InternationalDevelopment Limited("受让人")。根据可换股债券的条款及条件，除认购协议规定的特定情 形外，认购人未经公司事先书面同意，不得转让可换股债券。董事会认为，该转让并不构成可换股债券 条款的变动，且该转让不会影响公司及整体股东的利益。因此，公司已就该转让给予书面同意。 格隆汇10月30日丨环球医疗(02666.HK)发布公告，2025年10月30日，可换股债券的认购人CCP Leasing II Limited已将本金额合共为9000万美元的可换股债券转让("该转让")予Dragonland ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 （股份代號:2666） 完成可換股債券的轉讓 茲提述 (i) 本公司於二零二零年十二月二十九日及二零二一年三月二十五日就發行二零 二六年到期的 150,000,000 美元有擔保可換股債券刊發的公告（「該等公告」），以及 本公司於二零二一年一月十四日就該事項刊發的通函（「該通函」）；(ii) 本公司於二 零二一年六月十日、二零二二年六月十日、二零二三年六月十五日、二零二四年六月 十九日及二零二五年六月十九日就換股價格調整刊發的公告；及 (iii) 本公司於二零二 四年二月二十二日就認購人就本金額合共 60,000,000 美元的可換股債券部分行使認沽 期權刊發的公告。除非另有說明，本公告所用詞彙具有該等公告及該通函所界定的相 同涵義。 完成二零二六年到期可換股債券轉讓 通用環球醫療集團有限公司 GENERTEC UNIVERSAL M ...

Core Viewpoint - The company, Global Medical (02666.HK), reported a positive operational performance for the first three quarters of 2025, with significant growth in revenue and profit compared to the previous year [1] Financial Performance - For the nine months ending September 30, 2025, the company's revenue increased by approximately 12.8% compared to the same period last year [1] - The profit for the period rose by about 7.6% year-on-year [1] - The profit attributable to ordinary shareholders increased by approximately 4.2% compared to the previous year [1]

Core Insights - The company reported a steady improvement in overall operations for the first three quarters of 2025, with a revenue increase of approximately 12.8% and a profit increase of about 7.6% compared to the same period last year [1] - The company is actively responding to policy impacts such as healthcare payment reforms and centralized procurement, enhancing its medical service capabilities and optimizing its business structure [1][2] Financial Performance - For the nine months ending September 30, 2025, the profit attributable to ordinary shareholders increased by approximately 4.2% year-on-year [1] - The total revenue from medical services accounted for 36.5% of the overall income, reflecting a year-on-year increase of 2.3 percentage points [1] Operational Efficiency - The company has implemented various initiatives such as no-holiday outpatient services and extended hours for specialist consultations, resulting in a 3.4% increase in outpatient visits compared to the previous year [1] - The average length of hospital stay decreased to 9.1 days, while the total number of discharges increased by approximately 1.7% year-on-year, indicating improved operational efficiency [1] Cost Management - The company has strengthened cost control measures, particularly in drug and consumable management, leading to a reduction in the cost of medical supplies as a percentage of revenue from 44.9% to 43.0% [1] Strategic Development - In the specialized medical and health technology sectors, the company is focusing on both internal development and external expansion, with ongoing progress in layout expansion and capability building [2] - The financial business is transitioning towards four key areas: healthcare, equipment manufacturing, chemical pharmaceuticals, and innovative businesses, while also developing a new model combining financing leasing with full lifecycle management of medical equipment [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明,，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號:2666） 本集團未經審核二零二五年第三季度營運概要 專科醫療及健康科技方面，本集團圍繞核心醫療資源，堅持內涵式發展與外延式擴張「雙 輪驅動」，培育特色業務及核心能力，努力打造第二增長曲線。當前，此版塊在佈局拓展、 能力建設等方面已陸續取得進展，相關併購項目也在順利推進中。 通用環球醫療集團有限公司 本公告載列通用環球醫療集團有限公司（「本公司」或「環球醫療」）及其附屬公司 （「本集團」）截至二零二五年九月三十日止第三季度未經審核之營運概要。 本公告為根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及 香港法例第571章證券及期貨條例第XIVA部內幕消息條文（定義見上市規則）作出。 二零二五年前三季度，本集團整體經營穩中向好，各項重 ...

Core Points - The company announced the issuance of the third phase of its 2025 renewable corporate bonds by its wholly-owned subsidiary, China Global Leasing Co., Ltd [1] - The total principal amount of the bonds issued is RMB 300 million, with a fixed interest rate of 2.05% [1] - The bonds were successfully issued in China on October 28, 2025, with a basic term of 1 year [1] - The issuer has the right to exercise the renewal option at the end of the basic term and at the end of each renewal period [1] - The issuance price of the bonds is RMB 100 per bond, equivalent to 100% of the face value [1]

Core Viewpoint - The company announced the issuance of its third phase of renewable corporate bonds for 2025, totaling RMB 300 million, with a fixed interest rate of 2.05% [1] Group 1: Bond Issuance Details - The bonds were issued by the company's wholly-owned subsidiary, China Global Leasing Co., Ltd., within China [1] - The total principal amount of the bonds issued is RMB 300 million, with a base term of 1 year starting from October 28, 2025 [1] - The issuance price is set at RMB 100 per bond, equivalent to 100% of the bond's face value [1] Group 2: Terms and Conditions - The issuer has the right to exercise the renewal option at the end of the base term and at the end of each renewal cycle [1] - The fixed interest rate for the bonds is 2.05% [1]

Core Viewpoint - Global Medical (02666.HK) has issued the third phase of its 2025 renewable corporate bonds in China, totaling RMB 300 million with a fixed interest rate of 2.05% [1] Group 1: Bond Issuance Details - The total principal amount of the bonds issued is RMB 300 million [1] - The bonds have a base term of 1 year starting from October 28, 2025 [1] - The issuance price is set at RMB 100 per bond, equivalent to the face value of the bonds [1] Group 2: Renewal Option - The issuer has the right to exercise a renewal option at the end of the base term and at the end of each renewal cycle [1]

通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） (股份代號：2666) 本公司全資附屬公司中國環球租賃有限公司 完成二零二五年第三期可續期公司債券發行 本公告乃由通用環球醫療集團有限公司（「本公司」）根據香港聯合交易所有限公司證券上 市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部內幕 消息條文（定義見上市規則）作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 1 承董事會命 通用環球醫療集團有限公司 Genertec Universal Medical Group Company Limited 陳仕俗 董事會主席 中國北京， 二零二五年十月二十八日 於本公告日期，本公司的執行董事為陳仕俗先生（主席）、王文兵先生及王琳女士；本公司的非執行董事為童 朝銀先生、林春海先生及朱梓陽先生；而本公司的獨 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 （股份代號：2666） 持續關連交易 修訂 2024 年醫療相關產品採購框架協議、 2024 年醫療相關產品銷售框架協議 及 2024 年物業租賃框架協議項下的年度上限 GENERTE CUNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） 通用環球醫療集團有限公司 修訂2024年醫療相關產品採購框架協議項下的年度上限 茲提述本公司日期為 2023 年 11 月 23 日的公告，内容有關（其中包括）2024 年醫療相關 產品採購框架協議項下的持續關連交易及其年度上限。2023 年 11 月 23 日，本公司與通用 技術集團訂立 2024 年醫療相關產品採購框架協議，據此，本公司及╱或其附屬公司將向 通用技術集團及╱或其聯繫人採購醫療相關產品以及配套物流及倉儲服務。 鑒於截至2025年12月31日及2026年12月31日止兩個年度的現有年度上限預期不 ...